Skip to main content
Sign In

William J. Burman, MD



Phone:   303-436-8197
Address:  Denver Health Hospital
605 Bannock Street
Denver, Colorado



Medical School

Mayo Medical School


Fitzsimons Army Medical Center

Chief Medical Resident - Fitzsimons Army Medical Center


Infectious Diseases Fellowship - University of Colorado Denver

Clinical Activities

Medical Director of the Infectious Diseases Clinic of Denver Public Health

Medical Director of the HIV Care program of Panhandle Community Health Center, Scottsbluff, Nebraska

Attending physician in the Tuberculosis Clinic of Denver Public Health

My research interest is the design and implementation of randomized clinical trials to improve the treatment of tuberculosis and HIV infection. I am the Chair of the scientific planning committee of the Tuberculosis Trials Consortium (TBTC), an international multicenter clinical trials group funded by CDC. The TBTC is currently evaluating a 3-month, 13-dose regimen for treatment of latent tuberculosis and is doing a series of trials to identify shorter treatment regimens for active tuberculosis. Within the TBTC, I am also active in the Pharmacokinetics Working Group and a committee developing trial designs for multidrug-resistant tuberculosis.

I help design HIV treatment trials through the NIH-funded Community Programs for Clinical Research on AIDS. Recent efforts have focused on the assessment of quality-of-life and transmission risk behavior among patients randomized to different strategies of antiretroviral therapy (continuous vs. episodic therapy).

Within the ID Clinic of Denver Public Health, my research interest is in the evaluation and improvement of adherence with antiretroviral therapy. Finally, I do research on the epidemiology and treatment of drug-resistant bacterial infections (fluoroquinolone-resistant Escherichia coli, methicillin-resistant Staphylococcus aureus, etc.).

Pub Med Articles

  • Clancy M, Graepler A, Breese P, Price C, Burman W. The widespread emergence of methicillin resistance in community-acquired Staphylococcus aureus Infections in Denver. South Med J, 2005; 98: 1069-75.

  • Gardner E, Burman W, Maravi M, Davidson A. Selective drug taking during combination antiretroviral therapy in an unselected clinic population. JAIDS, 2005; 40: 294-300.

  • Burman W, Benator D, Vernon A, Khan A, Jones B, Silva C, LaHart C, Weis S, King B, Mangura B, Weiner M, El-Sadr W. Acquired rifamycin-resistance with twice-weekly treatment of HIV-related tuberculosis. Am J Respir Crit Care Med, 2006; 173: 350-6.

  • Jenkins T, Gardner E, Thrun M, Cohn D, Burman W. Risk-based HIV testing fails to detect the majority of HIV-infected persons in medical care settings. Sex Trans Dis, 2006; 33:329-333.

  • Gardner EM, Burman WJ, Maravi ME. Davidson AJ. Durability of adherence to antiretroviral therapy on initial and subsequent regimens. AIDS Patient Care STDs, 2006; 20: 628-36.

  • Burman W, Goldberg S, Johnson J, Muzanye G, Engle M, Mosher A, Choudri S, Daley CL, Munsiff S, Zhao Z, Vernon A, Chaisson R, and the Tuberculosis Trials Consortium. Moxifloxacin versus ethambutol in the first two months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med, 2006; 174:331-8.

  • The SMART Study Group (member of the writing group). CD4-guided antiretroviral treatment interruption. N Engl J Med, 2006; 355(22): 2283-96.

  • Weiner M, Burman W, Luo CC, Peloquin CA, Emgle M, Goldberg S, Agarwal V, Vernon A. Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin. Antimicrob Agents Chemother, in press.

  • Burman W. Issues in the treatment of HIV-related tuberculosis. Clin Chest Med, 2005; 26: 283-94.

  • Mitnick C, Castro K, Harrington M, Sacks L, Burman W. Randomized trials to optimize treatment of MDR-TB: the time for action is now. PLOS Medicine, in press.